Introduction
============

Remyelination is a successful regenerative event within the adult central nervous system (CNS), as it can restore saltatory conduction [@BIB58] and facilitate functional recovery [@BIB35]. Remyelination has been demonstrated in a variety of experimental demyelination/mutant models [@BIB8], [@BIB9], [@BIB10], [@BIB11], [@BIB16], [@BIB25], [@BIB28], [@BIB34], [@BIB35], [@BIB36], [@BIB38], [@BIB45], [@BIB55], [@BIB56], [@BIB70] and occurs spontaneously in naturally occurring demyelinating diseases such as MS [@BIB51]. However, remyelination failure is more prevalent than its success when considering the spectrum of pathologies that affect the CNS. Although remyelination is usually successful in most animal models, it is often incomplete in the Theiler\'s model of demyelination [@BIB46]. Furthermore, remyelination is less efficient in old animals than in young animals [@BIB57]. The failure of remyelination is illustrated within foci of chronic demyelination within the later stages of MS [@BIB52]. Chronic MS lesions are characterized by oligodendrocyte loss [@BIB48], with remyelination limited to the borders of inactive plaques [@BIB65].

Repairing persistent demyelination may ameliorate clinical deterioration. In addition to restoring normal impulse conduction [@BIB68], remyelination may decrease axonal degeneration/transection. This is suggested by the demonstration that chronically demyelinated axons are vulnerable to degeneration/transection and that axonal loss in the later stages MS contributes to clinical deterioration [@BIB6], [@BIB15], [@BIB67]. These findings underscore the importance of developing therapeutic strategies to enhance remyelination. One approach is to activate or enhance the response of endogenous mechanisms for repair, as has been demonstrated following growth factor administration in the experimental autoimmune encephalomyelitis (EAE) demyelination model [@BIB72], or passive transfer of antiserum [@BIB55] or purified immunoglobulin [@BIB54] from mice immunized with spinal cord homogenate into the Theiler\'s demyelination model [@BIB44]. An alternative approach to remyelinating areas of demyelination is the transplantation of remyelination-competent cells.

Stem cells and neural precursors represent attractive sources for the generation of remyelination-competent cells, as they can be readily amplified and differentiated to the oligodendrocyte lineage [@BIB2], [@BIB13]. Stem cell-derived glial precursors have been shown to myelinate following transplantation into the myelin-deficient rat [@BIB13], and neural precursor-derived glial-committed progenitors [@BIB2], [@BIB39] have been shown to myelinate following transplantation into regions of acute experimental demyelination [@BIB39]. More recently, intracerebroventricular or intrathecal implantation of neural precursors into the EAE demyelination model resulted in migration of transplanted cells into white matter and their differentiation to astrocytes and oligodendrocytes, although no assessment of their ability to myelinate was performed [@BIB3]. To determine whether transplantation represents a viable strategy for treating demyelination, it is necessary to better understand the range of environmental conditions that support transplantation-mediated remyelination.

In this study, we investigated the ability of the complex and reactive disease state of the chronic demyelinating MHV model of MS to support transplant-mediated remyelination. Intracerebral injection of the J2.2v-1 strain of MHV results in acute encephalomyelitis with demyelination, followed 10--12 days later by an immune-mediated demyelinating encephalomyelitis with hindlimb paralysis and progressive CNS destruction, including the initiation of new demyelination foci probably for the life of the mouse [@BIB19], [@BIB27], [@BIB40], [@BIB62], [@BIB63]. This model provides an environment of ongoing demyelinating pathogenesis, and is thus distinct from gliotoxin lesions. Intraspinal transplantation of glial-committed progenitors into the MHV model of MS resulted in extensive migration of transplanted cells, robust remyelination, axonal sparing, and behavioral improvement. These results show that transplant-mediated remyelination is possible following intraspinal transplantation into an environment of ongoing pathogenesis resembling MS.

Material and methods
====================

Cell culture
------------

Striata from 4 postnatal day 1 C57BL/6 mice were dissected, triturated, and maintained as previously described [@BIB2]. Trypan blue was used to determine cell viability. Cells were grown for 5 days as floating clusters in 6-well low-adherent plastic dishes (Corning Life Sciences Acton, MA) at an initial density of 2 × 10^6^ cells/5 ml of DMEM:F12, B27 supplement (Gibco-Invitrogen, Carlsbad, CA) with insulin, sodium selenite, transferrin, putrescin, progesterone, T3, detailed in [@BIB2], and 0.02 μg/ml epidermal growth factor (EGF; Sigma-Aldrich, St. Louis, MO). On day 2, culture supernatant containing the floating clusters was removed and centrifuged at 400× *g* for 5 min. Clusters were then resuspended in fresh media and added to new culture dishes. On day 3, 0.02 μg/ml EGF was added to the culture dishes. On day 4, clusters were washed, resuspended in fresh media, and added to new culture dishes. On day 5, clusters were incubated with 10 mM BrdU (Sigma-Aldrich) in the culture medium overnight. One culture dish was not labeled with BrdU to compare viability and differentiation in the presence and absence of BrdU. On day 6, cultures were prepared for transplantation. Clusters were dissociated with 0.05% Trypsin-EDTA (Invitrogen Canada Inc., Burlington, ON) for 5 min, triturated, centrifuged for 5 min at 400 × *g*, resuspended three times in calcium- and magnesium-free DMEM (Gibco-Invitrogen), and concentrated to a final density of 12 × 10^4^ cells/μl in the same media. The cell preparation was kept on ice for a maximum of 1 h before transplantation. On the day of transplantation, some cells were prepared for immunocytochemistry. Clusters were centrifuged for 5 min at 400 × *g* and resuspended three times in fresh media without EGF, and were plated on 10 mg/ml poly-[l]{.smallcaps}-lysine (Sigma-Aldrich) and 15 μg/ml laminin (Sigma-Aldrich) coated four chamber, imaging slides (Nalgene-Nunc International, Rochester, NY).

Immunocytochemistry
-------------------

To assess differentiation potential, cells were grown on imaging slides on adherent substrate for 7 days, then fixed in 4% paraformaldehyde (Fisher Scientific, Pittsburgh, PA) in PBS for 10 min and immunocytochemical staining was performed using standard protocols. Imaging chambers were blocked with 20% normal goat serum (NGS) (Chemicon, Temecula, CA) for 30 min at room temperature. Primary antibodies (polyclonal rabbit anti-GalC, Chemicon, 1:200 dilution in 4% NGS; monoclonal mouse anti-NeuN, Chemicon, 1:200 dilution in 10% NGS; polyclonal rabbit anti-GFAP, DAKO, Denmark, 1:200 dilution in 4% NGS; monoclonal mouse anti-CD 11 b, Serotec, UK, 1:200 dilution in 4% NGS; polyclonal rat anti-BrdU, Accurate Chemical and Scientific Corporation, Westbury, NY, 1:200 dilution in 4% NGS) were applied to imaging chambers overnight at 4°C. Imaging chambers were rinsed three times with PBS, incubated for 30 min in 4% NGS, and fluorescent-conjugated secondary antibodies (Alexa 488 or 594, goat anti-rabbit, goat anti-rat, or goat anti-mouse IgG H+L, 1:200 dilution in 4% NGS; Vector Laboratories, Burlingame, CA) was applied and incubated for 1 h at room temperature. Chambers were rinsed three times in PBS, and nuclear staining was conducted by exposing cultures to bis-benzimide (Hoechst 33258, Molecular Probes, Eugene, OR) for 10 min. Cell quantification was conducted using an Olympus AX-80 light microscope with a 20× objective. The percentage of immunopositive cells was determined by dividing the total number of immunopositive cells by the total number of Hoechst-positive cells in each imaging chamber, and averaging the results from three different imaging chambers per marker. A total of 1940 Hoechst-positive cells were counted for these analyses. Each 4-chamber imaging slide had one no-primary control chamber and three stained chambers for each of the markers mentioned above. Only immunopositive cells with clearly Hoechst-positive nucleus were counted.

MHV model
---------

Age-matched, weight-matched (20--22 g) male C57BL/6 mice (H-2^b^ background; National Cancer Institute, Bethesda, MD; *n* = 16) were anesthetized by methoxyflurane inhalation (Pitman-Moore Inc., Washington Crossing, NJ). Mice received intracerebral injections of 500 plaque forming units of the neurotropic corona virus MHV strain J2.2v-1 (kindly provided by J. Fleming, University of Wisconsin, Madison, WI), suspended in 30 μl of sterile saline [@BIB40]. Intracerebral injection of MHV results in a biphasic disease: acute encephalomyelitis with myelin loss, followed 10--12 days later by an immune-mediated demyelinating encephalomyelitis with hindlimb paralysis and progressive destruction of the CNS [@BIB19], [@BIB27], [@BIB40], [@BIB63]. Two of the MHV injected animals died during the first week post injection; there is an 80--90% survival rate of animals injected with this viral strain, and the animals usually die during the first 12 days of acute infection. If the animals survive the acute stage of disease there is \>95% chance of survival. Control (sham) animals (*n* = 8) were injected with 30 μl of sterile saline alone and did not develop any behavioral or histological deficits.

Transplantation
---------------

Twelve days after MHV intracerebral injection, each animal (*n* = 7) received a single injection of 240,000 cells in 2 μl of calcium- and magnesium-free DMEM (Gibco-Invitrogen) at T8 of the spinal cord, using the protocol described in [@BIB12]. Briefly, animals were anesthetized with Avertin and received a laminectomy at T8. The spinal process cranial to the laminectomy was immobilized using a micromanipulator and the transplant needle, a 10-μl Hamilton syringe (Hamilton Company, Reno, NV) with a silicon-coated pulled glass tip, was lowered into the spinal cord using a stereotactic manipulator arm. Cell suspensions were injected into one site at the midline of the spinal cord. The needle was removed from the cord 5 min after injection of the cells was complete. In addition, six control animals that received an MHV intracerebral injection received no transplant. One animal died during transplantation/anesthesia. Animals were randomly selected for inclusion in either group and all received an incision to the skin overlying T8 to allow blinded analyses for the duration of the experiment.

Behavioral testing
------------------

Behavioral testing of all animals was conducted by a blinded observer, every other day using the 4-point clinical scoring scale [@BIB32] where 0 = normal, 1 = limp tail, 2 = waddling gait and partial hindlimb weakness, 3 = complete hindlimb paralysis, 4 = death animal. This 4-point scale was supplemented with a single increment between each point, such that 1.5 = limp tail and partial waddling gait and no hindlimb weakness, 2.5 = hindlimb weakness and partial hindlimb paralysis, 3.5 = complete hindlimb paralysis and moribund disposition. Animals were acclimated and behaviorally tested 1 day before MHV injection. After MHV injection, animals were tested every day. After transplantation, animals were tested every other day for 2 weeks and then every 3rd day until the end of the experiment. Statistical significance was determined using the Mann--Whitney *U* test.

Histology
---------

Animals were euthanized under chloral hydrate anesthesia (Fisher Scientific) 21 days following transplantation or 33 days after MHV infection and fixed by cardiac perfusion with 4% paraformaldehyde (Fisher Scientific) in 0.1 M PBS, pH 7.4. The length of spinal cord extending 12 mm cranial and 10 mm caudal to the site of implantation was cut into 1-mm transverse blocks and processed so as to preserve the craniocaudal sequence and orientation. Alternating tissue blocks were processed for resin and cryostat sectioning and analyzed in a blinded fashion. Resin sections were used to determine the area of the ventral and lateral columns, and the number of demyelinated, remyelinated, and normally myelinated axons. Cryostat sections were used to determine spread of BrdU-prelabeled transplanted cells and their differentiation profile.

For resin sectioning, odd numbered blocks were post fixed in 4% glutaraldehyde (Fisher Scientific), then exposed to 1% OsO~4~ (Electron Microscopy Sciences, Fort Washington, PA), dehydrated in ascending alcohols, and embedded in Spurr resin (Electron Microscopy Sciences) according to standard protocols. Transverse semi-thin (1 μm) sections were cut from the cranial face of each block, stained with alkaline toluidine blue, cover slipped, and examined by light microscopy on an Olympus AX-80 microscope using OLYMPUS MicroSuite B3SV software. Total areas of the ventral and lateral columns were measured with the 4× objective and averaged. A *t* test was performed to compare the areas of the ventral and lateral columns in transplanted and non-transplanted animals. The state of myelination was determined by assessing the thickness of the myelin sheath in relation to the axon diameter [@BIB26], [@BIB29]. Demyelinated, remyelinated, and normally myelinated axons were counted within 4 × 3750 μm^2^ areas, totaling 15 000 μm^2^, on each tissue section using the 100× objective with 2× optical zoom. 15 000 μm^2^ represents approximately 10% of the total area of remyelination within transplanted animals, which was determined by measuring the total area of remyelination in tissue sections from each block in each animal using the 40× objective, and averaging areas from all animals in each group. These quantitative assessments were conducted throughout the region extending 8 mm cranial and 6 mm caudal to the implantation site. The number of demyelinated axons, remyelinated axons, the total number of axons (normally myelinated plus demyelinated plus remyelinated axons), and the percentage of remyelinated axons (number remyelinated/number total axons) were determined for each of the four regions on each tissue block, averaged, then averaged across animals within each group for each tissue block. A *t* test was performed to compare these values for transplanted and non-transplanted groups. To determine whether the number of remyelinated axons in each animal correlated with the total number of axons in each counting area, remyelinated and total axons counts were each averaged among all four counting areas for all blocks for each animal, and the correlation coefficient between these two values was determined for both transplanted and non-transplanted groups. Statistical analyses were conducted using SPSS software.

For cryostat sectioning, even numbered blocks were cryoprotected in 30% sucrose solution in PBS, embedded in OCT (Fisher Scientific) and frozen sectioned in the transverse plane at 20 μm on a JUNG CM3000 Leica cryostat for anti-BrdU staining. For BrdU staining, sections were washed in PBS, exposed to 50% formamide (Sigma-Aldrich) and 2N hydrochloric acid (Fisher Scientific) for 30 min at 37°C for DNA denaturation, followed by a 30-min exposure to 0.3% H~2~O~2~ in PBS, then incubated overnight at room temperature with rat anti-BrdU polyclonal antibody (Accurate Chemical and Scientific Corporation) at a 1:200 dilution in 4% NGS. Secondary antibody was biotinylated goat anti-rat heavy and light chain IgG (Sigma-Aldrich). Vectastain ABC (Vector Laboratories) and 3,3′-diaminobenzidine (Vector Laboratories) were used for signal visualization. The number of BrdU-positive cells was counted on three sections 80-μm apart from each tissue block for each animal using OLYMPUS MicroSuite B3SV software, and averaged. The numbers of BrdU-positive cells within corresponding blocks from animals within a group were then averaged. For BrdU, APC-CC1 double staining, sections were washed in PBS, exposed to 2N hydrochloric acid (Fisher Scientific) for 30 min at 37°C for DNA denaturation, and primary antibodies (rat anti-BrdU, 1:200, Accurate Chemical and Scientific Corporation; mouse anti-APC-CC1, 1:20, Oncogene Research Products, San Diego, CA) were diluted in 2% bovine serum albumin and applied to slides overnight at room temperature. Slides were rinsed three times with PBS, incubated for 30 min in 2% bovine serum albumin, and secondary antibodies (Alexa 488 or 594, goat anti-rat or goat anti-mouse IgG H+L, 1:200 dilution in 2% bovine serum albumin; Vector Laboratories) were applied and incubated for 1 h at room temperature.

Results
=======

In vitro differentiation of striatal cultures
---------------------------------------------

Trypan blue analysis indicated that approximately 1.1--1.2 × 10^6^ viable cells were obtained from each postnatal day 1 mouse. Floating cell clusters reached approximately 200 μm in diameter after 6 days of culture [(Fig. 1a)](#FIG1){ref-type="fig"} . On day 6, clusters were either (1) dissociated and transplanted into animals or (2) transferred to an adherent substrate in the absence of growth factors, grown for an additional 7 days and assayed for differentiation potential.Fig. 1The differentiation potential of striatal neural precursors can be restricted by culture conditions. (a) Cell cluster after 5 days of growth in non-adherent growth factor containing media, viewed in phase contrast. Cells were grown as free-floating clusters, reaching approximately 200 μm in diameter. (b) Hematoxylin--eosin-stained cell cluster 1 day after transfer to an adherent substrate. Cells spread out from clusters within 6 h of plating, and by 1 day, possess complex morphologies. (c) Multipolar GalC-positive (green) oligodendrocytes were abundant after 7 days of growth on adherent substrate in the absence of growth factors (Hoechst-positive nuclei are blue). (d) GFAP-positive (green) astrocytes were also abundant after 7 days of growth on adherent substrate in the absence of growth factors (Hoechst-positive nuclei are blue). (e) Few NeuN-positive (red) neurons were present (Hoechst-positive nuclei are blue). (f) The majority of cells (85 ± 10.7%) within cultures were BrdU-positive. This field illustrates BrdU-positive (red) GFAP-positive (green) astrocytes. (g) Quantification of cell types after 7 days of growth on adherent substrate in the absence of growth factors indicated that the differentiation protocol yielded 67.4 ± 4.4% oligodendrocytes, 26 ± 7.4% astrocytes, and 6.6 ± 6.2% other cell types, which included NeuN+ neurons, CD11b + microglia, and other Hoechst-positive cells not identified by the immunostains tested. Error bars represent standard deviation. 40× magnification for a and b, 100× for magnification for c, and d, 400× magnification for e, 200× magnification for f.

As early as 6 h after transfer of cell clusters to an adherent substrate and concomitant growth factor withdrawal, cells started to spread out from the adherent clusters and by 1 day, displayed complex cellular morphologies [(Fig. 1b)](#FIG1){ref-type="fig"}. After 7 days of growth on adherent substrate, oligodendrocytes and astrocytes could be identified by their morphology and immunolabeling. Oligodendrocytes displayed a multipolar morphology with membranous extensions and GalC immunoreactivity [(Fig. 1c)](#FIG1){ref-type="fig"}, whereas astrocytes displayed a flat or stellate morphology and GFAP immunoreactivity [(Fig. 1d)](#FIG1){ref-type="fig"}. Few NeuN immunoreactive neurons [(Fig. 1e)](#FIG1){ref-type="fig"} and CD11b immunoreactive microglia (results not shown) were detected. No-primary antibody control staining chambers had no positive staining. Different cell types often occupied discrete regions of the culture dishes. A total of 1940 Hoechst-positive cells were counted for the following analyses. Quantification of immunolabeled cells indicated that 85 ± 10.7% (range = 64--96, median = 80) of the total cell population was BrdU immunoreactive following an overnight pulse [(Fig. 1f)](#FIG1){ref-type="fig"}, and that the differentiation protocol yielded 67.4 ± 4.4% oligodendrocytes (range = 60--72, median = 66), 26 ± 7.4% astrocytes (range = 20--40, median = 30) and 6.6 ± 6.2% other cell types (range = 1--13, median = 7), which included NeuN + neurons, CD11b + microglia, and other Hoechst-positive cells not identified by the immunostains tested [(Fig. 1g)](#FIG1){ref-type="fig"}. No difference was observed in the viability or differentiation of BrdU-labeled or -unlabeled cells.

Histological outcome of glial-committed progenitor transplantation
------------------------------------------------------------------

Transplanted glial-committed progenitors, labeled with BrdU before implantation, survived and colonized long lengths of the spinal cord during the 21-day survival period [(Fig. 2)](#FIG2){ref-type="fig"} , and differentiated into mature oligodendrocytes [(Fig. 3)](#FIG3){ref-type="fig"} . BrdU-labeled cells were detected 12 mm cranial and 10 mm caudal to the site of implantation (the extent of tissue examined), and extended throughout the transverse plane of the spinal cord, primarily within white matter tracts. The number of BrdU-labeled cells was greatest around the site of implantation, and fell off sharply 4--6 mm either side of the site of implantation. BrdU-labeled cells were absent in non-transplanted animals [(Fig. 2c)](#FIG2){ref-type="fig"} and in no-primary antibody control stains of transplanted animals.Fig. 2Transplanted glial-committed progenitor cells survived and migrated during the 21-day survival period. (a): BrdU-stained transverse section of the spinal cord from a MHV-infected mouse 21 days following cell transplantation, 4 mm cranial to the site of implantation. BrdU-positive cells are abundant within the white matter tracts. Box is magnified in b. (b) BrdU-positive cells are evenly distributed within the lateral white matter tracts. (c) BrdU-stained transverse section of the spinal cord from a non-transplanted, MHV injected mouse 33 days following MHV injection. Note the absence of BrdU-labeled cells. (d) Distribution of BrdU-positive cells cranial and caudal to the site of implantation. Error bars represent standard deviation. 100× magnification for a, 400× magnification for b and c.Fig. 3Transplanted glial-committed progenitor cells differentiated into oligodendrocytes during the 21-day survival period. Double immunohistochemical stains for BrdU to identify transplanted cells and APC-CC1 to identify mature oligodendrocytes. (a) BrdU-stained transverse section of the spinal cord from a MHV-infected mouse 21 days following cell transplantation, 1 mm caudal to the site of implantation. (b) APC-CC1 immunostaining of the same section shown in A. (c) Overlay of a and b. Arrows indicate double-labeled BrdU and APC-CC1 cells, illustrating that transplanted cells differentiated into mature oligodendrocytes. Arrowheads indicate BrdU+ CC1− cells, illustrating transplanted cells that differentiated into other cell types. Arrow profiles indicate BrdU−, CC1+ cells, illustrating endogenous oligodendrocytes. 600× magnification.

Non-transplanted animals infected with MHV develop a demyelinating disease accompanied by mononuclear cell infiltration, widespread myelin destruction, and progressive degeneration of the CNS in the survivors [@BIB19], [@BIB27], [@BIB42], [@BIB63]. Systematic random analyses [(Fig. 4a)](#FIG4){ref-type="fig"} indicated that numerous demyelinated axons were present [(Figs. 4b, e, g)](#FIG4){ref-type="fig"} among vacuoles, myelin debris, activated macrophages, lymphocytes, and necrotic cells throughout the region of spinal cord examined, indicative of ongoing pathogenesis. The number of demyelinated axons was not significantly different (*P* \> 0.05) in transplanted and non-transplanted animals [(Fig. 5a)](#FIG5){ref-type="fig"} , likely because MHV is an ongoing demyelinating disease generating a similar number of newly demyelinated axons in both non-transplanted and transplanted animals. The number [(Fig. 5b)](#FIG5){ref-type="fig"} and percentage [(Fig. 5c)](#FIG5){ref-type="fig"} of remyelinated axons in non-transplanted animals was significantly lower (*P* \< 0.01) than in transplanted animals, and composed less than 10% of the total number of axons counted [(Fig. 5c)](#FIG5){ref-type="fig"}. Normally myelinated axons were exceedingly rare at this time point. Control animals injected with saline only did not develop clinical or histopathological deficit.Fig. 4Transplantation of glial-committed progenitor cells resulted in remyelination. (a) Toluidine blue-stained transverse section of a spinal cord from a transplanted animal showing the areas from which photographs and counts were taken. (b) Toluidine blue-stained transverse section of spinal cord white matter from an MHV-infected mouse 33 days after induction of disease illustrating the predominance of demyelinated axons (arrow). (c) Toluidine blue-stained transverse section of spinal cord white matter from an MHV-infected mouse 33 days after induction of disease and 21 days after transplantation of glial-committed progenitor cells. Note that the vast majority of axons bear thin myelin sheaths (arrow) characteristic of remyelination. (d) Toluidine blue-stained transverse section of spinal cord white matter from a normal mouse, indicating normal myelin sheath thickness (arrow), for comparison with panel c. (e) Electron photomicrograph of spinal cord white matter from an MHV-infected mouse 33 days after induction of disease illustrating a demyelinated axon (arrow) and a normally myelinated axon (arrowhead). (f) Electron photomicrograph of spinal cord white matter from an MHV-infected mouse 33 days after induction of disease and 21 days after transplantation of glial-committed progenitor cells. Note the thin myelin sheaths (arrow) characteristic of remyelination (for comparison, note the thickness of the normal myelin sheath in e (arrowhead). (g) Toluidine blue-stained transverse section of spinal cord white matter from an MHV-infected mouse 33 days after induction of disease illustrating the predominance of demyelinated axons amongst vacuoles, macrophages, lymphocytes, and an enlarged extracellular space. (h) Toluidine blue-stained transverse section of spinal cord white matter from an MHV-infected mouse 33 days after induction of disease and 21 days after transplantation of glial-committed progenitor cells. Note the higher proportion of remyelinated axons and total axon density as compared to non-transplanted animals (g). 40× magnification for a, 2000X for b--d, 39 000 for e and f, 800× magnification for g and h.Fig. 5Transplantation of glial-committed progenitor cells resulted in remyelination and axonal sparing. (a) Demyelinated axons were present in transplanted and non-transplanted animals; their numbers within 15 000 μm^2^ of white matter were not statistically different (*P* \> 0.05). (b) Remyelination extended 8 mm cranial and 6 mm caudal to the implantation site (arrow) in transplanted animals (the extent of tissue examined) and was significantly greater than the degree of remyelination in non-transplanted animals at every point examined (*P* \< 0.01). (c) Throughout this region, 54% to 67% of the total number of axons in the ventral and lateral columns of transplanted animals were remyelinated. Remyelination in non-transplanted animals was significantly less at every point examined (*P* \< 0.01). (d) The total number of axons within 15 000 μm^2^ of white matter in transplanted animals was approximately 2× the total number of axons within similar regions in non-transplanted animals (*P* \< 0.01 for all points), suggesting that remyelination is associated with axonal sparing. Error bars represent standard deviation.

Transplantation of glial-committed progenitors resulted in widespread remyelination [Fig. 4](#FIG4){ref-type="fig"}, [Fig. 5](#FIG5){ref-type="fig"}. Remyelinated axons were identified by their characteristically thin myelin sheaths [(Figs. 4c, f, h)](#FIG4){ref-type="fig"} and appeared in aggregates distributed throughout the dorsal, ventral, and lateral columns among demyelinated axons. Remyelination extended 12 mm cranial and 10 mm caudal to the implantation site in six of seven transplanted animals. Counts of remyelinated axons throughout the region extending 8 mm cranial and 6 mm caudal to the implantation site (the extent of our quantification; [Fig. 5b](#FIG5){ref-type="fig"}) indicated that regions of remyelination contained 54% to 67% remyelinated axons [(Fig. 5c)](#FIG5){ref-type="fig"}. Normally myelinated axons were exceedingly rare at this time point; note that for each tissue block, the number of remyelinated axons [(Fig. 5b)](#FIG5){ref-type="fig"} plus the number of demyelinated axons [(Fig. 5a)](#FIG5){ref-type="fig"} approximates the total number of axons [(Fig. 5d)](#FIG5){ref-type="fig"}. One transplanted animal contained few remyelinated axons, similar to non-transplanted animals (*P* \> 0.1); immunohistological analysis of this animal revealed that it contained no BrdU-positive cells. We did not observe tumor, teratoma, or non-neuronal tissue formation in transplant recipients, nor did we observe a qualitative difference in Schwann cell presence or remyelination between transplanted and non-transplanted animals.

Counts of the total number of axons (normally myelinated, demyelinated, and remyelinated) within the region extending 8 mm cranial and 6 mm caudal to the transplantation site (the extent of spinal cord examined) suggest that transplanted animals had significantly more axons (*P* \< 0.01) within the ventral and lateral columns as compared to non-transplanted animals [Fig. 4](#FIG4){ref-type="fig"}, [Fig. 5](#FIG5){ref-type="fig"}. Area measurements of the ventral and lateral columns revealed no significant difference between animals within and between the transplanted and non-transplanted groups (*P* \> 0.05, *t* test), however, a two-sample *t* test power analysis indicated that an experimental *n* of 6 per group was insufficient to conclude statistical significance of the differences between the groups. Nonetheless, these data suggest that the higher number of total axons within transplanted animals was not a result of tissue shrinkage in the transplanted animals. Comparison of the total number of axons with the number of remyelinated axons for each animal within the transplanted group indicated a statistically significant correlation between these two values (*r* = 0.953; *P* \< 0.05), indicating that a greater degree of axonal sparing correlated with a greater degree of remyelination.

Behavioral outcome of glial-committed progenitor transplantation
----------------------------------------------------------------

All transplanted animals survived for the duration of the experiment. Non-transplanted animals developed clinical disease typically characterized by a waddling gait and partial hindlimb weakness by 8--9 days post-infection, which progressed to complete hindlimb paralysis by 10 days post-infection, persisting for the duration of the experiment [(Fig. 6)](#FIG6){ref-type="fig"} . Control saline-injected animals displayed normal locomotor behavior throughout the duration of the experiment (all animals scored 0).Fig. 6Transplantation of glial-committed progenitor cells resulted in an improvement in locomotor abilities. Transplanted animals demonstrated a significant improvement (*P* \< 0.01) in locomotor abilities beginning 14 days after transplantation (arrow). From 24 days after induction of disease, transplanted animals walked with a waddling gait and partial hindlimb weakness, whereas non-transplanted animals demonstrated complete hindlimb paralysis. Error bars represent standard deviation.

Transplantation of glial-committed progenitors resulted in a significant improvement in locomotor abilities [(Fig. 6)](#FIG6){ref-type="fig"}. All transplanted animals had complete hindlimb paralysis at the time of transplantation. Six of seven transplanted animals demonstrated a significant (*P* \< 0.01) improvement in locomotor abilities beginning 14 days after transplantation, which progressed to weight-supported waddling locomotion with partial hindlimb weakness. One transplanted animal demonstrated no improvement in locomotor abilities; post-mortem analysis of this animal revealed that it contained no BrdU-positive transplanted cells and a degree of remyelination that was not significantly different (*P* \> 0.1) from non-transplanted animals.

Discussion
==========

Cell replacement strategies must contend with the fact that the differentiation of transplanted cells is strongly influenced by the environmental signals and cellular deficiencies operating at the site of implantation. For example, stem cells isolated from the adult hippocampus generate new hippocampal neurons and glia following transplantation into the hippocampi of other animals, while these same cells generate olfactory bulb neurons expressing appropriate neurotransmitter phenotypes following transplantation into the rostral migratory stream, or glial cells following transplantation into regions of the CNS which do not normally generate neurons in the adult [@BIB21], [@BIB64]. These influences present formidable challenges to cell replacement strategies aimed at promoting repair of neurodegenerative disease or injury due to the complex and reactive environment of such lesions, and point towards lineage commitment of multipotent cells before transplantation [@BIB37].

Our differentiation protocol resulted in the generation of oligodendrocytes and astrocytes in high yield (67.4% and 26%, respectively) from postnatal day 1 derived striatal neural precursors [(Fig. 1)](#FIG1){ref-type="fig"}, supporting previous studies using a similar differentiation protocol [@BIB2]. Cellular migration in vitro was evident as early as 6 h, and cellular differentiation in vitro was evident as early as 1 day, after transfer of cell clusters to an adherent substrate and concomitant growth factor withdrawal.

To assess migration and differentiation in vivo, undifferentiated prelabeled glial-committed progenitors were transplanted into regions of demyelination in the MHV model of MS. Intracerebral injection of the J2.2v-1 strain of MHV results in initial viral replication in the ependymal cells lining the ventricles, which subsequently extends to the central canal, gray and white matter of the spinal cord. Infectious virus is usually eliminated by days 12--14 post infection, but is not completely cleared. Acute encephalomyelitis with myelin loss is present by day 5 and extends rapidly in the anterior funiculi. An immune-mediated demyelinating encephalomyelitis with hindlimb paralysis and progressive destruction of the CNS then follows; although some remyelination takes place, the initiation of new foci of demyelination likely continues for the entire life of the mouse [@BIB19], [@BIB27], [@BIB40], [@BIB42], [@BIB62], [@BIB63]. In the current study, undifferentiated glial-committed progenitors were transplanted into the thoracic spinal cords of mice with fulminate demyelinating pathology and complete hindlimb paralysis as a result of MHV infection. Transplanted cells survived for the duration of the 21-day post-transplantation period and spread throughout the mediolateral extent of the spinal cord as well as 12 mm cranial and 10 mm caudal to the site of implantation, the extent of the tissue being examined [(Fig. 2)](#FIG2){ref-type="fig"}. These findings demonstrate that transplanted progenitor cells are capable of extensive migration throughout regions of ongoing pathogenesis. Survival and extensive migration of transplanted gliogenic cell populations has been demonstrated in the developing normal CNS [@BIB33], myelin-deficient mutant CNS [@BIB13], [@BIB22], [@BIB41], [@BIB66], chemically demyelinated CNS [@BIB24], [@BIB38], and in inflamed white matter tracts in the EAE model of MS [@BIB3], [@BIB50]. However, the ability of gliogenic cell populations to survive and migrate in these environments does not indicate that they will do so in the intact normal adult CNS. When glial progenitors [@BIB20], [@BIB47] are transplanted into the intact normal adult CNS, they fail to survive or migrate; only when the cells are placed in the immediate vicinity of active regions of demyelination, where survival factors are elevated [@BIB30], do they enter the lesion. These findings suggest that the survival and extensive migration of cells in our study was due in part to the continuity of pathology throughout the region of migration.

Transplantation of glial-committed progenitors resulted in extensive remyelination, ranging from 54% to 67% of the axons present within randomly selected regions of the spinal cord [Fig. 4](#FIG4){ref-type="fig"}, [Fig. 5](#FIG5){ref-type="fig"}. The in vitro [(Fig. 1)](#FIG1){ref-type="fig"} and in vivo [(Fig. 3)](#FIG3){ref-type="fig"} differentiation profile of these cells, the presence of extensive remyelination only in transplanted animals [(Figs. 5b, c)](#FIG5){ref-type="fig"}, and the presence of remyelination throughout the region over which transplanted cells migrated [Fig. 2](#FIG2){ref-type="fig"}, [Fig. 5](#FIG5){ref-type="fig"} suggest that remyelination was conducted by the transplanted cell population. Nonetheless, we cannot rule out the possibility that remyelination in transplanted animals was carried out by endogenous cells that may have been activated as a result of trophic support by the transplanted population.

Cumulative axonal loss has recently been demonstrated in several human [@BIB4], [@BIB18], [@BIB67] and rodent [@BIB6], [@BIB23], [@BIB74] demyelinating pathologies, using in vivo magnetic resonance imaging [@BIB61], [@BIB69], in vivo magnetic resonance spectroscopy [@BIB1], [@BIB43], morphological analysis of brain sections [@BIB18], [@BIB67], and biochemical methods [@BIB7]. Chronic demyelination is a probable cause of such axonal loss [@BIB5]. To determine whether remyelination was associated with axonal sparing in the current study, total axon numbers were determined within the ventral and lateral columns of transplanted and non-transplanted animal groups 33 days after induction of disease. Although the area of the ventral and lateral columns were not significantly different between the transplanted and non-transplanted groups (*P* \> 0.05, *t* test), the total number of axons within the ventral and lateral columns of transplanted remyelinated animals was approximately 2× the number of axons within the ventral and lateral columns of non-transplanted animals [(Fig. 5d)](#FIG5){ref-type="fig"}. Furthermore, comparison of the total number of axons with the number of remyelinated axons for each animal within the transplanted group indicated a statistically significant correlation between these two values (*r* = 0.953). These findings suggest that a greater degree of axonal sparing correlated with a greater degree of remyelination. Reduced axonal loss has also been shown after intravenous or intrathecal neurosphere transplantation in the EAE mouse model of MS [@BIB50]. These data support the view that chronic demyelination is a cause of axonal loss, and suggest that transplant-mediated remyelination protects axons from degeneration/transection. Further studies are required to determine the molecular mechanisms underlying demyelination-associated axonal degeneration/transection.

Transplantation of glial-committed progenitors resulted in a significant improvement in locomotor abilities beginning 14 days after transplantation, which progressed to weight-supported waddling locomotion with partial hindlimb weakness [(Fig. 6)](#FIG6){ref-type="fig"}. Non-transplanted animals remained completely paralyzed throughout this time period [(Fig. 6)](#FIG6){ref-type="fig"}. In regions of experimental demyelination induced by lysolecithin [@BIB58], [@BIB59], [@BIB73] or ethidium bromide [@BIB17], return of secure axonal conduction occurs at the same time as spontaneous remyelination and transplanted glial cells have been shown to improve conduction velocity to near-normal values in myelin-deficient rats [@BIB68] and ethidium bromide lesions [@BIB31]. Transplantation of clonal neural cells into the intracerebroventricular system of the shiverer mice at birth resulted in myelination of up to 52% of host neuronal processes and reduced the symptomatic tremor in some animals [@BIB71]. Thus, it is intriguing that the time course of behavioral improvement following transplantation in the current study approximates the time required for remyelination [@BIB49], [@BIB59].

Our findings demonstrate that transplant-mediated remyelination is possible in the complex and reactive environment of the MHV model of multiple sclerosis. Transplant-mediated remyelination has been demonstrated in regions of the CNS subjected to experimental demyelination or in myelin mutants, environments that are characterized by a clear cellular deficit, a largely non-reactive CNS environment, and a lack of inflammation. Thus, transplantation of embryonic stem cell-derived precursors [@BIB13] or oligodendrocyte progenitors [@BIB75] into postnatal myelin-deficient rats resulted in differentiation of transplanted cells into myelinating oligodendrocytes and astrocytes. Multipotential PSA-NCAM + neural precursors isolated from the postnatal rat brain have been shown to differentiate into oligodendrocytes, Schwann cells, and astrocytes following transplantation, to completely remyelinate regions of acute demyelination in the adult rat induced by ethidium bromide injection into x-irradiated dorsal column white matter [@BIB39]. Similarly, transplantation of embryonic stem cells into regions of ethidium bromide induced demyelination in the adult rat spinal cord or into myelin-deficient shiverer mutant mice, resulted in the generation of stem cell-derived oligodendrocytes that were capable of myelinating axons [@BIB41]. More recently, transplant-mediated remyelination has been illustrated in the EAE model of MS, following intravenous or intrathecal injection of adult neural precursor cells [@BIB50]. Our findings confirm and extend those outlined above, in demonstrating that intraspinal transplant-mediated remyelination can occur in the fulminate neurodegenerative environment of the MHV model of MS and is associated with locomotor improvement.

The ability of glial cell preparations to remyelinate in such models does not necessarily indicate that their transplantation into demyelinated lesions in clinical disease will be successful [@BIB60]. Firstly, transplanted cells may be subject to the same demyelinating process that led to the development of the initial pathology. Notably, the viral 'trigger' of pathology in the MHV model of MS is largely cleared by 12 days post-infection [@BIB40], [@BIB62], before the time of implantation in the current study. Secondly, the inability of glial progenitors to migrate through normal tissue [@BIB47] renders them less than ideal for remyelinating disparate foci of demyelination as seen in clinical disease [@BIB51]. Thirdly, human transplantation necessitates a human progenitor or stem cell population that is capable of amplification and is myelinogenic. Although robust amplification of human embryonic stem cells has been achieved [@BIB14], [@BIB53], the conditions needed to differentiate them into a remyelination-competent transplant population have not yet been defined. And fourthly, the gliotic environment of clinical lesions, which may contribute to the failure of endogenous remyelination, may prohibit the transplant population from effecting repair. Clearly, several key issues must be addressed before a cellular replacement strategy can be considered for the treatment of human demyelinating pathologies such as MS.
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